Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Jun 20;15(2):98912.
doi: 10.5662/wjm.v15.i2.98912.

Enhancing the outcomes of diabetic vitrectomy with pharmacological adjuvants

Affiliations
Editorial

Enhancing the outcomes of diabetic vitrectomy with pharmacological adjuvants

Chun-Yao Cheng et al. World J Methodol. .

Abstract

This editorial offers insights from a minireview by Venkatesh et al, who explored pharmacological adjuvants for diabetic vitrectomy. Specifically, they synthesized current knowledge and evaluated the efficacy of various adjunctive therapies in improving the outcomes of diabetic retinopathy and managing associated complications. Herein, we highlight the key roles of pharmacological adjuvants in optimizing surgical techniques, minimizing intraoperative challenges, and enhancing postoperative recovery. We further discuss the potential implications of this approach for clinical practice and future research directions in this evolving field. Overall, this editorial underscores the importance of incorporating pharmacological adjuvants into standard diabetic vitrectomy care to improve surgical outcomes and thus patients' quality of life.

Keywords: Clinical implications; Diabetic retinopathy; Diabetic vitrectomy; Pharmacological adjuvants; Surgical outcomes.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Similar articles

References

    1. Venkatesh R, Jayadev C, Prabhu V, Gandhi P, Kathare R, Yadav NK, Choudhary A, Chhablani J. Pharmacological adjuvants for diabetic vitrectomy surgery. World J Methodol. 2024;14 - PMC - PubMed
    1. Fadakar K, Rahmani S, Tedeschi T, Lavine JA, Fawzi AA. Short Term Effect of Pre-Operative Anti-VEGF on Angiogenic and Fibrotic Profile of Fibrovascular Membranes of Proliferative Diabetic Retinopathy. Invest Ophthalmol Vis Sci. 2024;65:37. - PMC - PubMed
    1. Gurelik IG, Ozdemir HB, Acar B. The effect of adjuvant Mitomycin C during vitrectomy on functional and anatomical outcomes in patients with severe diabetic tractional retinal detachment. Int Ophthalmol. 2024;44:210. - PubMed
    1. Santra M, Sharma M, Katoch D, Jain S, Saikia UN, Dogra MR, Luthra-Guptasarma M. Enzymatic vitreolysis using reengineered Vibrio mimicus-derived collagenase. Mol Vis. 2021;27:125–141. - PMC - PubMed
    1. Hisatomi T, Tachibana T, Mori K, Ishikawa K, Ishibashi T, Sonoda KH, Uchio E, Watanabe I, Suzuki K, Iida M. Injectable in situ cross-linking hyaluronan hydrogel for easier removal of posterior vitreous cortex in vitrectomy. Jpn J Ophthalmol. 2024;68:146–156. - PubMed

Publication types

LinkOut - more resources